Erin Chang gained her Master of Science degree from the Graduate Institute of Toxicology at the National Taiwan University. She has more than 19 years of experience in new drug development and project management and worked at TTY Biopharm, Taiwan Liposome Company (TLC) and BRIM Biotechnology, Inc.

Erin is experienced in the incubation of academic projects, drug development, clinical development, portfolio and risk management, patent portfolio management. She was also responsible for the corporate operation management and IPO at BRIM Biotechnology, Inc. Erin has participated in the discovery and clinical development of biologics, peptides, and special dosage new drugs for IND, ph1, ph2 and ph3 studies.